Reprogramming the Tumor Immune Microenvironment with ICAM‐1‐Targeted Antibody‒Drug Conjugates and B7‐H3‐CD3 Bispecific Antibodies
Advanced Science · 2025-04 · 12 (16)
DOI: 10.1002/advs.202415577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 25.02.2025. Verfasst von Shoubing Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Tumor Microenvironment, B7 Antigens, Intercellular Adhesion Molecule-1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Innovative Research Group Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Reprogramming the tumor immune microenvironment (TIM) plays an important role in promoting the reversal of immune “cold” tumors into “hot” inflammatory tumors. Improving drug targeting, blocking immune checkpoints, and promoting the activation of immune cells are crucial for reprogramming the TIM. Here, an intercellular adhesion molecule 1‐targeted antibody‒drug conjugate in combination with a B7‐H3‐CD3 bispecific antibody is selected for TIM reprogramming, which improved the efficacy of triple‐negative breast cancer immunotherapy. This combination therapy improves drug targeting, blocks immune checkpoint pathways, and activates effector T cells to release cytokines, leading to immunogenic cell death and the release of tumor‐associated antigens. This effect promotes the maturation of dendritic cells, infiltration and activation of cytotoxic CD8+ T cells, repolarization of M1‐type macrophages, and reduction of M2‐type macrophages, immune suppressor Tregs, and MDS cells, thereby reprogramming the TIM. In addition, this innovative strategy promotes the accumulation of immune cells at metastasis sites and significantly impedes the progression of lung metastatic lesions. Overall, this study provides novel insights for reprogramming the TIM using novel immunotherapeutic strategies that leverage the synergistic effects of antibody‐drug conjugates and bispecific antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230031, China.
- Department of Breast Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, 230031, China.
- Laboratory of Structural Immunology, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, He…
- Department of Tumor Radiotherapy, People Hospital of Fengyang County, Chuzhou, Anhui, 233100, China.
- Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
- Department of Oncology, Suzhou Hospital of Anhui Medical University, Suzhou, 234000, China.
ORCID-Profile: Shoubing Zhou
Förderung
- National Key Research and Development Program of China
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Zhou, S., Hong, M., Zhao, D., Li, W., Yuan, X., Wang, Y., Li, H., Yang, Y., Jin, T., & Pan, J. (2025). Reprogramming the Tumor Immune Microenvironment with ICAM‐1‐Targeted Antibody‒Drug Conjugates and B7‐H3‐CD3 Bispecific Antibodies. Advanced Science, 12(16). https://doi.org/10.1002/advs.202415577
Vancouver
Zhou S, Hong M, Zhao D, Li W, Yuan X, Wang Y, et al. Reprogramming the Tumor Immune Microenvironment with ICAM‐1‐Targeted Antibody‒Drug Conjugates and B7‐H3‐CD3 Bispecific Antibodies. Advanced Science. 2025;12(16). doi:10.1002/advs.202415577
BibTeX
@article{Zhou2025,
author = {Zhou, Shoubing and Hong, Mengyu and Zhao, Dan and Li, Wenyu and Yuan, Xiaolong and Wang, Yinghong and Li, Hualong and Yang, Yang and Jin, Tengchuan and Pan, Jing},
title = {Reprogramming the Tumor Immune Microenvironment with ICAM‐1‐Targeted Antibody‒Drug Conjugates and B7‐H3‐CD3 Bispecific Antibodies},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {16},
doi = {10.1002/advs.202415577}
}
EUVIMED